Condition: Degenerative Disc Disease (DDD) · Sponsor: ReGelTec, Inc.
A multi-center, prospective, dual arm, randomized, controlled pivotal study to evaluate the safety and effectiveness of the ReGelTec HYDRAFIL™ System.
This description comes directly from the study's public registry record.
Seth Kaufman · 443-451-3915
Elisa B Storyk, MPH, CCRP · 443-451-3915
Always discuss trial participation with your own doctor first.
| Alabama Clinical Therapeutics | Birmingham, Alabama, United States | Recruiting |
| Source Healthcare | Santa Monica, California, United States | Recruiting |
| Boomerang Healthcare (IPM Medical Group) | Walnut Creek, California, United States | Recruiting |
| DBPS Research (The Denver Spine & Pain Institute) | Greenwood Village, Colorado, United States | Recruiting |
| The Orthopaedic Institute | Gainesville, Florida, United States | Recruiting |
| Southwest Florida Pain Center | Port Charlotte, Florida, United States | Recruiting |
| NRSA Group (Florida Spine & Pain Specialists) | Riverview, Florida, United States | Recruiting |
| Horizon Clinical Research (Southern Pain and Spine) | Jasper, Georgia, United States | Recruiting |
| Neuroscience Research Center, LLC | Overland Park, Kansas, United States | Recruiting |
| Spine Institute of Louisiana (The Spine Network) | Shreveport, Louisiana, United States | Recruiting |
| Clinical Investigations | Edmond, Oklahoma, United States | Recruiting |
| Precision Spine Care | Tyler, Texas, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06011551